All Releases
 |
SciClone to Present at Jefferies 2013 Global Healthcare Conference
May 28, 2013
|
10.7 KB |
| |
FOSTER CITY, CA -- (Marketwired) -- 05/28/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Jefferies 2013 Global Healthcare Conference on June 5, 2013 at 12:30 pm ET at the Grand Hyatt Hotel in New York City.
...
|
|
SciClone Reports Anticipated Financial Results for the First Quarter 2013
May 16, 2013
|
15.9 KB |
| |
FOSTER CITY, CA -- (Marketwired) -- 05/16/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported its expectations regarding financial results for the quarter ended March 31, 2013.
Friedhelm Blobel, Ph.D., SciClone Chief Executive Officer, commented: "The accounting treatment for portions of our NovaMed promotion services...
|
|
SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China Market
May 16, 2013
|
13.8 KB |
| |
FOSTER CITY, CA -- (Marketwired) -- 05/16/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company has entered into an agreement with Zensun (Shanghai) Science & Technology Co., Ltd. granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin...
|
|
SciClone Appoints PricewaterhouseCoopers LLP as Its Independent Registered Public Accounting Firm
Apr 8, 2013
|
10.0 KB |
| |
FOSTER CITY, CA -- (Marketwired) -- 04/08/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the Audit Committee of the Company's Board of Directors has appointed PricewaterhouseCoopers LLP ("PwC") as its independent registered public accounting firm, effective immediately, to perform independent audit services beginning with t...
|
|
SciClone Reports 2012 Financial Results and 2013 Outlook
Apr 1, 2013
|
27.7 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 04/01/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and for the year ended December 31, 2012.
Overall revenues increased $23.7 million or 18% for the full year 2012 to $156.3 million, compared to $132.6 million for the prior year, inc...
|
|
SciClone Pharmaceuticals to Report 2012 Financial Results and 2013 Outlook on April 1st
Apr 1, 2013
|
11.0 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 04/01/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report 2012 financial results and 2013 outlook today, Monday, April 1, 2013. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET today. The call will be hosted by Fried...
|
|
SciClone Appoints Hong Zhao as Chief Executive Officer, China Operations
Mar 22, 2013
|
11.9 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 03/22/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Hong Zhao as Chief Executive Officer, China Operations. Mr. Zhao is an accomplished, respected pharmaceutical industry executive with more than 20 years of experience in leading the commercial operations, market expans...
|
|
SciClone Provides Update on the Timing of Filing Its 2012 Annual Report on Form 10-K
Mar 14, 2013
|
10.2 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 03/14/13 --
As previously reported on February 22, 2013, SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is restating its financial statements for fiscal year 2011 and the first three quarters of fiscal 2012. The Company is in the process of completing the restatement of the financials and the Company's Annual ...
|
|
SciClone to Restate Financial Statements for 2012 and 2011 Periods
Feb 22, 2013
|
11.5 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 02/22/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will be restating its financial statements for each of the first, second and third quarters of 2012 and financial statements for each of the second and third quarters of 2011 and for the year ended December 31, 2011. The restate...
|
|
SciClone to Present at BIO CEO & Investor Conference on February 12th
Feb 4, 2013
|
10.8 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 02/04/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 2:00 pm ET at the Waldorf Astoria Hotel in New...
|
|
SciClone Announces Product Promotion Agreement Renewal With Key Industry Parnter Sanofi in China
Jan 30, 2013
|
11.3 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 01/30/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has successfully negotiated renewals of its exclusive product promotion agreement with Sanofi for the China market.
Under the terms of the Sanofi agreement, SciClone, through its wholly owned subsidiary, Novamed Ph...
|
|
SciClone Announces Appointment of Simon Li to Its Board of Directors
Jan 14, 2013
|
12.1 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 01/14/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Simon Li to its board of directors. Mr. Li is an accomplished and respected leader in the pharmaceutical and medical device industries in China and Asia, and brings to SciClone's board more than 30 years of experience ...
|
|
SciClone Provides Initial 2013 Financial Guidance
Jan 7, 2013
|
11.7 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 01/07/13 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated 2013 initial revenue, earnings per share (EPS) and year-end cash guidance, and 2012 year-end cash position, as follows:
The Company anticipates 2013 sales revenue of $150 million - $155 million.
The Com...
|
|
SciClone to Present at Oppenheimer 23rd Annual Healthcare Conference on December 13th
Dec 5, 2012
|
9.0 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 12/05/12 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 23rd Annual Healthcare Conference on December 13, 2012 at 11:10 am ET at the Waldorf-Astoria Hotel in New York City...
|
|
SciClone Announces New ZADAXIN(R) Anti-Counterfeiting Label Wins Major Industry Award
Dec 4, 2012
|
10.8 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 12/04/12 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its newly created anti-counterfeiting Pharma-Comb Void label for ZADAXIN has won the prestigious "Innovator Award" in the annual competition sponsored by the Tag and Label Manufacturers Institute (TLMI). The ZADAXIN label, which was...
|
|
SciClone to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th
Nov 12, 2012
|
9.0 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 11/12/12 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012 at 2:00 pm ET at the Pierre Hotel in New York City.
...
|
|
SciClone Reports Financial Results for the Third Quarter 2012 and 2012 Outlook
Nov 9, 2012
|
31.2 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 11/09/12 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter and for the nine months ended September 30, 2012. In the third quarter, ZADAXIN® sales continued to perform well, with 12% revenue increase in the quarter and 22% increase year to date compared...
|
|
SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2012 and 2012 Outlook on November 9th
Nov 8, 2012
|
9.6 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 11/08/12 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2012 financial results and 2012 outlook on Friday, November 9, 2012. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be...
|
|
SciClone Announces China Government-Mandated ZADAXIN(R) Price Reduction; Anticipates Minimal Impact on Revenue and Margins
Sep 18, 2012
|
12.8 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 09/18/12 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that consistent with the China government's review of pharmaceutical prices once a product has been included into the Reimbursement Drug List ("RDL"), the retail list price, or hospital pharmacy level price, of ZADAXIN® has been red...
|
|
SciClone Announces Management Transitions in China Operations
Sep 10, 2012
|
11.5 KB |
| |
FOSTER CITY, CA -- (Marketwire) -- 09/10/12 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Mark Lotter will resign from the position of Chief Executive Officer of SciClone's China Operations at the end of this year and plans to relocate from Shanghai to London in order to spend more time with his family. At that time Mr. ...
|
|
|
